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Abstract
Angiogenesis is regulated by hyperglycemic conditions, which can induce cellular stress 
responses, reactive oxygen species (ROS), and anti-oxidant defenses that modulate intracellular 
signaling to prevent oxidative damage. The RUNX2 DNA-binding transcription factor is activated 
by a glucose-mediated intracellular pathway, plays an important role in endothelial cell (EC) 
function and angiogenesis, and is a target of oxidative stress. RUNX2 DNA-binding and EC 
differentiation in response to glucose were conserved in ECs from different tissues and inhibited 
by hyperglycemia, which stimulated ROS production through the aldose reductase glucose-
utilization pathway. Furthermore, the redox status of cysteine and methionine residues regulated 
RUNX2 DNA-binding and reversal of oxidative inhibition was consistent with an endogenous 
Methionine sulfoxide reductase-A (MsrA) activity. Low molecular weight MsrA substrates and 
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sulfoxide scavengers were potent inhibitors of RUNX2 DNA binding in the absence of oxidative 
stress, but acted as antioxidants to increase DNA binding in the presence of oxidants. MsrA was 
associated with RUNX2:DNA complexes, as measured by a sensitive, quantitative DNA-binding 
ELISA. The related RUNX2 protein family member, RUNX1, which contains an identical DNA-
binding domain, was a catalytic substrate of recombinant MsrA. These findings define novel redox 
pathways involving aldose reductase and MsrA that regulate RUNX2 transcription factor activity 
and biological function in ECs. Targeting of these pathways could result in more effective 
strategies to alleviate the vascular dysfunction associated with diabetes or cancer.
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Introduction
Angiogenesis contributes nutrients and energy for tumor growth and is an essential 
component of wound healing (Potente et al., 2011). We, and others, have shown that rodents 
exhibit deficits in angiogenesis with age that account for the reduced growth of tumors and 
poor wound healing (Pili et al., 1994; Sato, 2003). One of the hypotheses proposed to 
explain these reduced angiogenic responses with aging is the elevation of ROS as a 
consequence of impaired antioxidant defenses (Lass et al., 1998). Angiogenesis is regulated 
by the coordinated expression of many cytokines, receptors, and transcription factors (DNA 
binding or associated factors) that control the expression of genes important in vascular 
endothelial cell (EC) migration, invasion, proliferation, and survival (Cao, 2014). One of 
these transcription factors, the Runt domain family member RUNX2, has been shown by our 
laboratory (Sun et al., 2001) and others (Namba et al., 2000) to regulate EC migration, 
invasion, differentiation, proliferation, and survival. RUNX2 promotes angiogenesis through 
expression of angiogenic cytokines, matrix molecules, and metalloproteinase target genes 
(Bronckers et al., 2005; Qiao et al., 2006; Qiao et al., 2004; Sun et al., 2001; Sun et al., 
2004). RUNX2 knockout mice exhibit defects in placental vessels (Komori et al., 1997), 
skin and hair follicle development (Glotzer et al., 2008), and fail to express VEGF in 
hypertrophic chondrocytes, resulting in lack of blood vessel infiltration and no bone 
formation (Zelzer et al., 2001). Adult RUNX2(+/−) heterozygote mice, but not young mice 
exhibit poor wound healing after bone marrow ablation (Juttner and Perry, 2007; Tsuji et al., 
2004).
Oxidative stress in mammalian cells reflects a balance between the production of reactive 
oxygen species (ROS) and the activation of antioxidant pathways (Jones, 2008), which 
regulate angiogenesis (Brautigam et al., 2013; Sohal and Orr, 1998). ROS contribute to 
immune responses, act as essential physiological signaling molecules that regulate basic cell 
biology (Hamanaka and Chandel, 2010), and promote oxidative damage with age (Stadtman 
et al., 2005). Sources of ROS are numerous and include ligand/receptor activation 
(Sundaresan et al., 1996) and enzymatic generation (Leto and Geiszt, 2006) while ROS 
targets include all components of the cell including proteins, lipids, and nucleic acids 
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(Kohen and Nyska, 2002; Wood et al., 2003). Cellular oxidant sensors and antioxidant 
defenses consist of DNA damage response enzymes (ribonucleotide reductases), superoxide 
dismutase and catalase, Keap1/Nrf1-induced activation of antioxidant genes (Kohen and 
Nyska, 2002), the thioredoxin/thioredoxin reductase complex, Ref1 response systems (Gius, 
2004), and the protein repair enzymes Methionine sulfoxide reductases (MsrA; MsrB) (Oien 
and Moskovitz, 2008). The Msr enzymes not only act directly on oxidized methionine 
(MetO) residues to restore transcriptional activity of proteins such as p53 (Hanson et al., 
2005; Nomura et al., 2009) but can also reduce overall cellular ROS by neutralizing H2O2 in 
the presence of sulfoxide antioxidant scavenger substrates (Weissbach et al., 2005). These 
enzymes play important roles in anti-oxidant defenses and oxidative stress-related 
neurological malfunction (Fomenko et al., 2009; Moskovitz et al., 2001; Moskovitz et al., 
1995; Oien et al., 2008; Oien et al., 2010; Ortiz et al., 2011), controlling transcriptional 
activation (Agbas and Moskovitz, 2009), and targeting proteins for proteolytic degradation 
(Oien et al., 2009b; Stadtman et al., 2003). Therefore, identification of new target proteins 
that might be regulated by Msr antioxidant activity will be important in understanding how 
cellular ROS control cell signaling, transcriptional activation, enzymatic function, and 
aging.
RUNX2 expression is downregulated in hyperglycemic (HG) diabetic mice, which may 
account for the observed angiogenic dysfunction in these mice (Fowlkes et al., 2008; Lu et 
al., 2003). Recent findings from our laboratory revealed that RUNX2 is regulated by 
nutrients in the microenvironment and its DNA-binding activity is especially sensitive to 
glycemic status (D’Souza et al., 2009). HG inhibited, while anti-oxidants increased, RUNX2 
activity and wound healing (D’Souza et al., 2009). Glucose activated RUNX2 DNA binding 
by increasing phosphorylation through the cdk pathway, which is less active in HG (Pierce 
et al., 2012). RUNX2 DNA binding may be sensitive to oxidation because of the presence of 
two conserved cysteine (Cys) residues in the Runt DNA binding domain that are necessary 
for correct protein folding and interaction with DNA (Akamatsu et al., 1997; Kurokawa et 
al., 1996). DNA binding is also controlled by the presence of a conserved Met residue in the 
Runt domain that mediates heterodimer formation with the RUNX2 binding partner, Cbfβ, 
which enhances DNA binding ten-fold relative to the RUNX2 monomer (Tahirov et al., 
2001). However, the possible role of HG stress in regulating the redox status of Met residues 
in RUNX2:Cbfβ interactions has not been studied.
To test the hypothesis that HG activation of the AR pathway in ECs could lead to elevated 
oxidative stress and negative regulation of RUNX2, we examined EC redox status in HG 
and how this affects RUNX2 DNA binding. We found that HG regulated RUNX2 activation 
through the AR glucose utilization pathway by elevating redox stress. Maintenance of 
RUNX2 activity was mediated by the Met-specific MsrA system, which can restore global 
redox balance of Cys residues after oxidative stress and regulates the redox status of critical 
Met residue(s) in the DNA-binding Runt domain of RUNX2. The results from this study 
provide new evidence that RUNX2 activity is regulated by glycemic status and oxidative 
stress. This may encourage new approaches to modulate the redox status of ECs to inhibit 
tumor angiogenesis or alleviate the vascular dysfunction associated with diabetes (Cao et al., 
2011).
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2,2-Bis(3-allyl-4-hydroxyphenyl) hexafluoropropane was prepared by dissolving 
hexafluorobisphenol A and K2CO3 in acetone (200 ml) and heating to reflux. After 30 min, 
allyl bromide was added drop wise and the resulting mixture was stirred at reflux for an 
additional 7 h and concentrated under reduced pressure. The remaining residue was taken up 
in ethyl acetate, washed with water and brine, dried over MgSO4, and concentrated under 
reduced pressure. BCl3 in dichloromethane was added drop wise to a solution of the crude 
2,2-bis(4-allyloxyphenyl)hexafluoropropane in dry dichloromethane (100 ml) at −78 °C. 
The resulting mixture was allowed to reach room temperature and stirred for another 3 h. 
The reaction mixture was quenched with water (100 ml), extracted with chloroform, washed 
with brine, dried over MgSO4, and concentrated under reduced pressure. The crude product 
was purified by flash chromatography to generate 2,2-bis(3-allyl-4-hydroxyphenyl) 
hexafluoropropane as a yellow oil. For DNA-binding assays, sulindac sulfoxide or sulfide 
was diluted from a 100 mM stock in 100% ethanol. Control treatment with ethanol alone 
(<0.1%) did not affect DNA binding.
Cell culture
Human bone marrow microvascular ECs (HBME) were obtained from Dr. Ken Pienta 
(University of Michigan); human microvascular adipose-derived ECs (HAdEC) were 
prepared by Dr. John McLenithan (NORC core facility at the University of Maryland); 
human microvascular dermal ECs (HMEC1) were obtained from the Centers for Disease 
Control and Prevention, Atlanta, GA; human retroviral telomerase (HRVT) ECs were 
prepared in our laboratory by infecting primary human umbilical vein endothelial cells 
(Huvec from Cell Systems, Kirkland, WA) with a retroviral vector expressing the human 
telomerase gene (hTert) from Dr. R. Weinberg (Counter et al., 1998); rat pancreatic β-cells 
(RINr) were a generous gift from Dr. Jun Hayashi (A&G Pharmaceuticals, Columbia, MD). 
All cells, except HRVT ECs, were cultured in DMEM + 10%FBS (complete medium) (Qiao 
et al., 2006); HRVT ECs were cultured in endothelial basal media (EBM2) plus growth 
supplements and 2% FBS (Lonza, Gaithersburg, MD). In some experiments, cells were 
cultured in glucose and serum-free, phenol red-free, DMEM supplemented with pyruvate, 
NaHCO3 (starvation medium). Cells were routinely tested for Ac-LDL uptake (fluorescence 
microscopy) and CD31 expression (FACS analysis) to confirm endothelial origin.
Measurement of redox status
For ROS measurements, cells were harvested, and replated for 24 h to 48 h in defined 
medium containing 5 mM or 25 mM glucose prior to preparation of nuclear extracts for use 
in Western blots. The aldose reductase (AR) inhibitors alrestatin (Tocris Cookson, Inc. 
Ellisville, MO) or ranirestat (AS-3201; Eisai Limited, United Kingdom) and the ROS 
quencher N-acetyl Cys (NAC; Sigma-Aldrich, St. Louis, MO), were used as antioxidants. 
Cellular ROS was measured using the CDCF-DA reagent (Enzo Life Sciences, New York, 
NY; #52103). Briefly, cells were cultured in black 96-well tissue culture plates for 2 days 
and starved for 16 h prior to glucose or oxidant treatments. After 20 min, the plate was 
washed with PBS and CDCF-DA (2 μM) was added for 20 min at 37 °C. Fluorescence was 
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measured using 485 nm/528 nm excitation/emission wavelengths. Redox status was 
determined by measuring the levels of NADP+, NADPH, and reduced glutathione (GSH). 
The NADP/NADPH Quantification Kit (Cell Technology, Inc., Mountain View, CA) was 
used to measure the ratio of NADP/NADPH without interference from NAD/NADH. A 
standard curve using NADPH was generated in a cycling reaction with reaction product 
detected at 450 nm. The fluorescent thiol detection kit (Cell Technology, Inc. Mountain 
View, CA) was used to measure GSH levels. Monitoring fluorescence emission at 515–530 
nm with excitation at 488 nm generated a GSH standard curve.
Antibodies, Western blots, and IP protocol
Western blot protocols were described previously (Vitolo et al., 2007). Protein concentration 
was determined with the Bio-Rad Protein Assay. Specific proteins were detected by 
enhanced chemiluminescence (Immobilon Western, Millipore, Inc., Billerica, MA). Co-
immunoprecipitation assays used the RUNX2-specific antibody (MBL D130-3, Woburn, 
MA) to isolate RUNX2 followed by Western blotting with the Cbfβ-specific antibody 
(Aviva Systems Biology, San Diego, CA). MsrA antibody (ab-16803) was from Abcam 
(Cambridge, MA) and anti-MetO antibody was used as described previously (Oien et al., 
2009a).
EC tube formation and wound healing in response to oxidants
ECs were isolated from subconfluent growing cultures and replated on 96-well plates 
containing 50 μl of matrigel (BD Biosciences) per well in the presence or absence of the 
indicated oxidants or antioxidants. Tube formation was documented for 16 h with a Nikon 
TMS microscope equipped with a digital camera. Images were quantified for tube formation 
by scanning (n = 3–4 fields per treatment) using the generic gray gamma 2.2-profiler in the 
Apple ColorSync Utility (version 4.6.2) program. Mean ± SD (representing arbitrary units 
(AU) of cellular area) and p-values were calculated from Excel spreadsheets using Student’s 
t-Test. In some cases, images were quantified for tube formation by counting the number of 
nodes per well, with nodes defined as the intersection of at least 3 tubular structures and 
were expressed as mean number of nodes ± SD.
DNA-binding electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assays (EMSA) were used to measure RUNX2 DNA-binding 
activity as described previously (Qiao et al., 2006). Nuclear proteins (5 mg) isolated by the 
low salt/high salt method were diluted in binding buffer and incubated with a double-
stranded (32P)-labeled oligonucleotide derived from the human osteocalcin promoter (−141 
to −165) containing the human RUNX2 consensus binding sequence (shown in bold): 5′-
CGTATTAACCACAATACTCG-3′. Specific binding complexes were resolved on DNA 
retardation gels (Invitrogen Corporation, Mountain View, CA).
DNA-binding enzyme-linked immunosorbent assay (D-ELISA)
DNA binding was quantified with a specific ELISA format method (Renard et al., 2001) as 
modified for RUNX2-specific detection (Underwood et al., 2012). Avidin-coated 96-well 
plates were fixed with sodium carbonate for 2 h at 24 °C. After rinsing 3× with wash buffer, 
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a 3′-biotin labeled oligonucleotide containing 3 osteocalcin RUNX2-binding sites was added 
for 2 h. Wash buffer was used after each of the subsequent steps of the assay. Nuclear 
extracts containing RUNX2 protein were exposed to the plate with rocking for 16 h at 4 °C. 
Primary antibody (for RUNX2) was added for 1 h at 24 °C and a secondary antibody-HRP 
was allowed to react with the primary antibody for 30 min at 24 °C. RUNX2 antibody 
(MBL, 1:5000) or MsrA Ab (Abcam, 1:1000) or non-specific IgG (1:1000) was used. TMB 
substrate (50 μl) was allowed to react with the HRP in the dark. Once color development 
was confirmed (10–20 min), 50 μl of stop solution was added to each well. A BioTrak II 
plate reader spectrophotometer (Amersham Biosciences/GE Healthcare, Piscataway, NJ) 
was used to obtain absorbance readings (A450 nm). For continuous (kinetic) monitoring of 
each reaction, automated absorbance readings were determined each minute at 635 nm with 
equivalent results using a BIO-TEK Synergy HT (Biotek Industries, Winooski, VT) and 
analyzed with Gen 5 Data Analysis Software.
Recombinant RUNX1 and MsrA
Human recombinant RUNX1 (rRunx1; NM_001001890) was obtained from Origene, Inc. 
(Rockville, Md). This protein contains a DNA-binding Runt domain that is 96% identical to 
the RUNX2 DNA-binding domain. It was produced by transient transfection of the 
TrueORF clone, RC223854, which contains a C-terminal Myc/DDK tag in HEK293T cells. 
Cells were lysed 48 h after transfection in modified RIPA buffer (25 mM Tris-HCl pH7.6, 
150 mM NaCl, 1% NP-40, 1 mM EDTA, 1× proteinase inhibitor cocktail mix (Sigma), 1 
mM PMSF and 1 mM Na3VO4), and recombinant protein was purified through anti-DDK 
affinity columns. Protein concentration was measured by BCA kit. RUNX1 protein was 
stored in 10% glycerol, 100 mM glycine, 25 mM Tris-HCl, and pH 7.3 at −80C. 
Recombinant human MsrA was obtained from Sigma-Aldrich (M8698; St. Louis, MO), was 
produced in Escherichia coli, and was stored in buffered aqueous solution at >8 U/mg 
protein where 1 Unit of recombinant protein is defined as the oxidation of 1 mmol of 
NADPH per minute at 37 °C at pH 7.6. For D-ELISA measurements, 0.24 μg of MsrA was 
used for each treatment (1.92 mU). For analysis of rRunx1 Met oxidation, 0.1 μg of MsrA 
was used for each treatment (0.8 mU). Western blots were used to detect Met-sulfoxide 
(MetO) with anti-MetO antibody (Oien et al., 2009a). Gels were stripped and reprobed with 
anti-MsrA antibody (Abcam ab16803).
Statistical analysis
Results for culture assays were calculated from at least three replicate samples and 
expressed as the mean (±SD) per data point. Western blot quantitation of scanned gels (n = 3 
per lane) used the generic gray gamma 2.2 profiler in the Apple ColorSync Utility (version 
4.6.2) program. Results from in vivo experiments were calculated from 4–6 data points 
(matrigel angiogenesis assays). To determine statistical significance, comparison of 
measurements relative to control samples used Student’s t-test. For comparison of multiple 
measurements, Tukey’s post-hoc adjustment for 2-by-2 comparisons following ANOVA 
was used for data analysis. p-values < 0.05 were considered significant.
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HG and oxidants inhibit RUNX2 DNA-binding and EC differentiation
Hyperglycemia (HG) elevates oxidative stress through the aldose reductase (AR) alternative 
glucose utilization pathway, which inhibits RUNX2 activity in bone marrow EC (HBME) 
without altering the levels of total RUNX2 protein (D’Souza et al., 2009). To determine 
whether this response was conserved in other cells, primary adipose (HAdEC), dermal 
(HMEC1), and umbilical vein (HRVT) ECs, as well as the classic glucose-responsive cell, 
the pancreatic β-cell (RINr) were treated with glucose after starvation to lower basal levels 
of RUNX2 DNA binding. Treatment with 5 mM glucose (euglycemic conditions) increased 
DNA binding. However, hyperglycemia (HG; 25 mM glucose) was not as effective at 
stimulating DNA binding in these cells (Fig. 1A). The antioxidant NAC restored RUNX2 
DNA binding in HG (HBME, HAdEC, HRVT) to levels observed in 5 mM glucose, 
suggesting that the RUNX2 response to glucose and the anti-oxidant effect were conserved 
in several ECs (Fig. 1A). Several pro-oxidants are well-known inhibitors of protein tyrosine 
phosphatases through inactivation of a Cys residue in the enzyme active site (Miki and 
Funato, 2012). These oxidants (VAN and PAO) were as effective as H2O2 or curcumin at 
inhibiting RUNX2 DNA binding in 5 mM glucose (Fig. 1B; lanes 1–7). The anti-angiogenic 
agents honokiol (Fig. 1B; lane 8) and hexafluoro-(HF)-honokiol (Fig. 1B; lanes 10–13) were 
also potent inhibitors of RUNX2 DNA binding. This inhibition may be mediated by the AR 
pathway since the AR inhibitor alrestatin restored RUNX2 DNA binding in the presence of 
honokiol (Fig. 1B; lane 9), consistent with our previous report showing that the AR pathway 
mediates RUNX2 inhibition in HG (D’Souza et al., 2009).
RUNX2 regulates EC tube formation on extracellular matrix, a measure of differentiation 
during angiogenesis (Sun et al., 2001). Since HG and oxidants inhibited RUNX2 DNA 
binding (Fig. 1A, Fig. 1B), we tested whether oxidants inhibited EC tube formation. Several 
oxidants potently and completely inhibited EC tube formation in 5 mM glucose (Fig. 1C). 
To determine whether HG regulated EC differentiation, tube formation using nutrient-
starved ECs on matrigel was performed. The addition of 5 mM glucose promoted tube 
formation, but not 25 mM glucose (Fig. 2A). Improved EC differentiation (5× increase) was 
observed in HG if cells were treated with the AR inhibitor ranirestat (Fig. 2A) consistent 
with improved EC wound healing using the related inhibitor, alrestatin, in HG (D’Souza et 
al., 2009). Further, treatment of cells with nM doses of ranirestat also prevented HG-induced 
inhibition of RUNX2 DNA-binding (Fig. 2B).
The AR pathway alters redox status in ECs exposed to HG
Activation of the AR pathway by HG can lead to elevated oxidative stress and the depletion 
of NADPH, a glutathione reductase cofactor used to generate reduced glutathione (GSH) 
(Brownlee, 2001). AR inhibitors can restore RUNX2 DNA binding in HG (D’Souza et al., 
2009) and have been used to reduce flux through the AR pathway (Srivastava et al., 2005). 
To determine if HG-associated ROS was responsible for inhibition of RUNX2 activity and 
EC differentiation, we measured cellular ROS levels in ECs exposed to HG. The levels of 
total ROS were measured using the fluorescent indicator CDCF-DA, which detects both 
superoxide anion ( ) and hydrogen peroxide (H2O2). Cells under glucose starvation 
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exhibited 2-fold greater ROS levels than cells that were treated with euglycemic (5 mM) 
levels of glucose for 4 h (Fig. 3A). However, treatment with 25 mM glucose (HG) did not 
lower ROS levels. Cells treated with the oxidants H2O2 or diquat in 5 mM glucose also 
exhibited elevated ROS while cells treated with the osmotic control sugar, mannitol, did not. 
Inhibition of AR with two different AR inhibitors (alrestatin or ranirestat) did not lower 
ROS levels in cells cultured under HG conditions. Two measures of oxidative stress in cells 
are the levels of reduced glutathione (GSH) and the ratio of oxidized NADP+ to reduced 
NADPH. Cells under oxidative stress generally exhibit high NADP:NADPH ratios 
(Brownlee, 2001). To determine if elevated ROS stress was dependent on the AR pathway, 
alrestatin (D’Souza et al., 2009) and ranirestat (Fig. 2) were used. Enzymatic assays to 
measure the levels of GSH, NADPH, and NADP+, confirmed that cells treated with 5 mM 
glucose exhibited low levels of oxidative stress (lower NADP+:NADPH) relative to starved 
or HG-treated (25 mM glucose) cells (Fig. 3B). Treatment with HG (25 mM glucose) did 
not lower the NADP+:NADPH ratio but inhibition of AR with alrestatin or ranirestat (Fig. 
3B) reduced the NADP+:NADPH ratio 5 to 10-fold, suggesting that AR contributed to 
increased oxidative stress in HG. Starvation or glucose treatment after starvation did not 
have a significant impact on cellular redox status as measured by reduced glutathione (GSH) 
levels (Fig. 3C). However, inhibitors of AR in 25 mM glucose increased the levels of GSH 
by 1.5 to 2-fold.
Role of cysteine and methionine residues in RUNX2 DNA binding
Cysteine (Cys) and Methionine (Met) residues in proteins that are sensitive to oxidative 
stress regulate transcription factor DNA binding (Brash and Havre, 2002; Hanson et al., 
2005). The DNA-binding Runt domain of RUNX2 contains two oxidation-sensitive Cys 
residues that mediate proper folding for Arg+/DNA interactions and DNA binding 
(Akamatsu et al., 1997; Kurokawa et al., 1996). A critical Met residue within the Runt 
domain also mediates association with its essential cofactor Cbfβ, which increases DNA 
binding 10-fold relative to Runt alone (Tahirov et al., 2001). Using a quantitative DNA-
binding assay (D-ELISA) specific for RUNX2 (Underwood et al., 2012; Underwood et al., 
2013), we showed that RUNX2 with a Cys mutation in the Runt domain (Cys118Ser) did 
not bind DNA (Underwood et al., 2012). Furthermore, a GFP-tagged Runt domain vector 
mutated at position Met-143 of the Runt domain (which inhibits Cbfβ binding) exhibited 
reduced DNA binding relative to wild type Runt domain (Underwood et al., 2012). The Cys-
selective oxidant diamide (Akamatsu et al., 1997) dose-dependently inhibited endogenous 
RUNX2 DNA binding, which was completely reversed by addition of the reducing agent 
DTT at 24 °C (Fig. 4A). Treatment of nuclear extracts with H2O2, which oxidizes both Cys 
and Met residues (Winterbourn and Hampton, 2008), inhibited RUNX2 activity as well. 
This inhibition was not reversible when nuclear extracts were incubated at 24 °C for 30 min, 
but was reversible after incubation at 37 °C for 30 min (Fig. 4A). To further characterize this 
response, redox reactions were carried out for various periods of time at 37 °C after 
oxidation at 24 °C. EC nuclear extracts prepared without DTT exhibited an initial lower 
level of DNA binding relative to RUNX2 prepared with DTT (Fig. 4B). Without DTT, DNA 
binding declined with incubation at 37 °C. Nuclear extracts prepared with DTT in the 
extraction buffer maintained stable RUNX2 DNA binding when incubated at 37 °C. As 
expected, RUNX2 DNA binding was almost completely abolished by H2O2 but addition of 
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DTT to the H2O2 treated nuclear extracts resulted in a rapid increase in RUNX2 DNA 
binding, reaching an activity equal to unoxidized samples within 20 min at 37 °C (Fig. 4C), 
consistent with an antioxidant and possibly enzymatic response.
Redox regulation of RUNX2 by Met-sulfoxide reductase (MsrA) substrates
Oxidized Cys residues in proteins can be reduced with endogenous (GSH) or exogenous 
(DTT) reducing agents. However, reduction of oxidized Met (sulfoxides) requires the 
Methionine sulfoxide reductase (Msr) system consisting of two genes encoding MsrA and 
MsrB enzymes, which can reduce the S-form or the R-form of the sulfoxide stereoisomer, 
respectively (Moskovitz et al., 2000; Moskovitz et al., 2002). To determine if endogenous 
MsrA was present in the nuclear extracts from ECs and if it was associated with RUNX2 in 
a DNA-binding complex, nuclear extracts were incubated with DNA oligonucleotide 
specific for RUNX2 and reacted with MsrA antibody. DNA binding was measured 
spectrophotometrically using the D-ELISA quantitative method (Fig. 5A, MsrA antibody). 
These nuclear extracts also contained RUNX2 (Fig. 5A, RUNX2 antibody). Nonspecific 
IgG was the negative control. MsrA (but not MsrB) enzymatic activity is sensitive to 
exogenous sulfoxide substrates, such as dimethyl sulfoxide (DMSO) or sulindac — a 
sulfoxide compound (Weissbach et al., 2005). DMSO inhibited RUNX2 DNA binding in a 
dose-dependent manner with half-maximal inhibition at 0.1% DMSO (not shown). DMSO 
also inhibited (by 50%) the ability of DTT to restore RUNX2 activity after H2O2 treatment 
(Fig. 5B). MsrA converts sulindac sulfoxide to sulindac sulfide, which is an ROS scavenger 
that can be oxidized to sulindac, leading to depletion of free radicals in the presence of 
MsrA (Weissbach et al., 2005). Treatment of RUNX2 nuclear extracts with sulindac in the 
absence of H2O2 (active RUNX2) resulted in a dose-dependent inhibition of RUNX2 DNA 
binding with significant inhibition between 1 and 100 μM (Fig. 5C, upper curves −H2O2). 
Sulindac sulfide was not an effective inhibitor, except at higher concentrations (500 μM). In 
the presence of H2O2 (low RUNX2 activity), addition of sulindac sulfoxide (10nM) restored 
about 50% while addition of sulindac sulfide restored about 40% of the original RUNX2 
DNA-binding activity, consistent with H2O2 quenching (Fig. 5C, lower curves +H2O2).
Redox regulation of RUNX2 and RUNX1 by MsrA
As a further test of MsrA-regulated RUNX2 DNA binding, EC nuclear extracts were treated 
with recombinant MsrA after oxidation and DNA binding was continuously monitored in a 
kinetic reaction (absorbance, 635 nm) as described (Underwood et al., 2012). Treatment of 
RUNX2 nuclear extracts with 1 μM H2O2 inhibited RUNX2 DNA binding by 50% relative 
to untreated samples (Fig. 6A). Addition of DTT (30 mM) and recombinant MsrA restored 
RUNX2 DNA binding to levels 24% higher than pretreatment (after 1 μM H2O2). Treatment 
with DTT and MsrA (without prior H2O2 treatment) also increased DNA binding by 24% 
(Fig. 6A). These samples were incubated at 37 °C, which is optimal for the MsrA reaction. 
Incubation of nuclear extracts at 37 °C with DTT after H2O2 treatment also restored RUNX2 
activity, without the need for recombinant MsrA (Fig. 6A), consistent with the presence of 
MsrA in the RUNX2:DNA complexes (Fig. 5A). To detect endogenous MsrA, nuclear 
extracts were isolated from live cells that had been incubated with the oxidants H2O2 or 
honokiol and MsrA was immune-purified with an MsrA-specific antibody. Recombinant 
MsrA was used as a positive control (Fig. 6B, lane 1). MsrA protein (26 kDa) was present in 
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nuclear extracts from untreated cells (Fig. 6B, lane 2). Reduced levels of MsrA were evident 
in nuclear extracts from honokiol-treated cells (Fig. 6B, lane 3) but not from H2O2-treated 
cells (Fig. 6B, lane 4) relative to untreated controls. The amount of RUNX2 protein 
associated with MsrA was lower by 6-fold in H2O2-treated cells (Fig. 6B, lane 4). Mutation 
of a specific Met residue in the Runt-homology DNA binding domain (RHD) inhibits 
interactions of RUNX2 with its binding partner Cbfβ and reduces DNA binding (Tahirov et 
al., 2001). ECs were starved and treated with 5 mM glucose or 5 mM glucose + H2O2 before 
isolation of nuclear extracts and immunoprecipitation with anti-RUNX2 antibody. The 
levels of Cbfβ associated with RUNX2 increased 2.4-fold in cells treated with 5 mM 
glucose, relative to untreated cells, while H2O2 prevented the glucose-mediated increase in 
associated Cbfβ (Fig. 6C).
RUNX1 contains a DNA-binding Runt domain (and conserved Met residue that regulates 
Cbfβ binding) that is 96% identical to the RUNX2 Runt domain at the amino acid level 
(Blyth et al., 2005). Since recombinant RUNX2 was not available, recombinant RUNX1 
(rRUNX1) was used as a surrogate to determine whether Met residues in RUNX1 could be 
directly oxidized to Met sulfoxide (MetO) by H2O2. rRUNX1 at 24 °C, exists as a 49 kDa 
monomer and a 98 kDa dimer (Fig. 6D; lane 2) while rMsrA resolved at 26 kDa (Fig. 6D; 
lane 3) when probed with anti-MetO antibody. Incubation of rRUNX1 with rMsrA/DTT at 
24 °C resulted in the expected oxidized rRUNX1 and rMsrA species (Fig. 6D; lane 4). 
However, incubation of rRUNX1 with rMsrA/DTT at 37 °C resulted in reduced MetO 
antibody reactivity for monomeric or dimeric rRUNX1 and for rMsrA itself (Fig. 6D; lane 
5). When H2O2 was included in the incubation mixture with rRUNX1 and rMsrA/DTT at 37 
°C, reduction of rRUNX1 was not observed (Fig. 6D; lane 6). These results suggest that 
MsrA can associate with RUNX2 in EC nuclear extracts and that RUNX1 can function as an 
MsrA substrate.
Discussion
HG conditions contribute to vascular dysfunction, cardiovascular disease and stroke, and are 
associated with diabetes (Aronson, 2008; Cao, 2013; Kim et al., 2006). HG can also 
modulate EC redox status (Brownlee, 2001) and many cells, including ECs, adapt to 
oxidative stress by inducing an antioxidant response that provides the cells with an added 
survival advantage (Hamanaka and Chandel, 2010). Modulation of cellular ROS balance in 
ECs could, therefore, either “normalize” dysfunctional vessels or destabilize existing vessels 
to inhibit angiogenesis. Characterization of redox pathways that regulate the RUNX2 
transcription factor is important in understanding vascular dysfunction associated with 
aging, diabetes, and cancer. Glucose levels and post-translational phosphorylation regulate 
RUNX2 DNA binding (Pierce et al., 2012). We have now found that euglycemic levels of 
glucose activated RUNX2 DNA binding and that ECs exposed to HG exhibited increased 
ROS and oxidative stress, which resulted in the inhibition of RUNX2 DNA-binding activity. 
HG increased ROS production and inhibited DNA binding through an AR alternative 
glucose utilization pathway. In contrast, MsrA, an enzyme that repairs protein Met residues 
and mediates cellular anti-oxidant defenses (Moskovitz, 2005; Stadtman et al., 2005), 
restored RUNX2 DNA binding under oxidative stress conditions.
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HG inhibited RUNX2 DNA binding in a variety of human ECs, including immortal 
(HBME; HMEC1) and primary (HRVT; HAdEC) cells (Fig. 1) while the general anti-
oxidant N-acetyl-cysteine (NAC) alleviated this repression. Interestingly, in HAdECs, NAC 
decreased basal DNA binding in the absence of glucose, which suggests that some oxidation 
events may lead to activation of RUNX2 DNA binding (D’Souza et al., 2009; Leto and 
Geiszt, 2006). HG can elevate cellular ROS in ECs and may have global effects on redox 
balance. We have shown that inhibition of AR with alrestatin or selective knockdown with 
siRNA targeting AR prevented HG-induced inhibition of RUNX2 activity and deficiencies 
in EC wound healing (D’Souza et al., 2009). Inhibition of AR with two different compounds 
(alrestatin; ranirestat) lowered cellular oxidative stress in HG and increased RUNX2 DNA 
binding (Figs. 2 and 3). Although AR inhibition did not appear to decrease the overall levels 
of ROS in 25 mM glucose, the anti-oxidant response (NADP:NADPH and GSH) was 
increased with AR inhibitor treatment (Fig. 3). These results suggest that HG may exert its 
inhibitory effects on RUNX2 and angiogenesis by lowering the overall anti-oxidant response 
in these cells. Therefore, blockade of glucose utilization by the AR pathway could reduce 
oxidative stress and alleviate the EC dysfunction associated with diseases such as diabetes, 
which are characterized by HG and hyperinsulinemia (Kim et al., 2006).
RUNX2 is a nuclear protein in proliferating ECs (Qiao et al., 2006) and glucose activation 
does not depend on new mRNA or protein synthesis (D’Souza et al., 2009). RUNX2 DNA 
binding was very sensitive to low doses of diamide (a Cys-selective reagent) or H2O2 (Fig. 
4), which oxidizes both Cys and Met residues in proteins (Winterbourn and Hampton, 
2008). Diamide treatment of the RUNX2 DNA-binding domain inhibited DNA binding 
activity (Akamatsu et al., 1997; Kurokawa et al., 1996). This inhibition was partially or fully 
reversed by treatment with the reducing agents DTT, GSH, Trx, or Ref1. We observed 
similar results with wild type (full-length) RUNX2 DNA binding using DTT as a reducing 
agent, which reversed diamide-induced oxidation and restored RUNX2 activity. H2O2-
induced oxidation of RUNX2 DNA binding was not reversed by treatment with DTT at any 
dose when samples were incubated at 24 °C (Fig. 4). Since Met residues are oxidized by 
H2O2 and are not reduced by DTT alone (Oien and Moskovitz, 2008), we incubated nuclear 
extracts with recombinant MsrA at 37 °C. MsrA was able to restore RUNX2 activity above 
control levels in the presence of DTT. If MsrA were acting as a general antioxidant to 
neutralize H2O2, then all Cys residues would be in a reduced form and all RUNX2 activity 
would be restored. Nuclear extracts prepared without DTT in the extraction buffer exhibited 
lower RUNX2 DNA-binding activity than did extracts containing DTT, suggesting that 
either some RUNX2 protein was already oxidized or that MsrA was in an oxidized state. 
Therefore, restoration of RUNX2 activity after DTT addition in the absence of recombinant 
MsrA is consistent with an endogenous MsrA activity. MsrA protein was found associated 
with RUNX2 either in the presence of DNA (Fig. 5A) or in the absence of DNA using 
immunoprecipitation (Fig. 6B). Although DTT can be used as a reducing agent to regenerate 
active MsrA in this system, it is likely that nuclear extracts contain other components of the 
redox system to maintain homeostasis. For example, endogenous reducing agents such as 
NADPH are cofactors for thioredoxin reductase (TrxR) to regenerate thioredoxin (Trx) and 
activate Msr enzymes (Gius, 2004; Moskovitz et al., 2001; Stadtman et al., 2005; Weissbach 
et al., 2005).
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Sulfoxides are low molecular weight antioxidants (LMWA) that act as scavengers of ROS 
(Kohen and Nyska, 2002). DMSO inhibited RUNX2 DNA binding and prevented 
restoration of H2O2-inhibited activity after DTT treatment (Fig. 5). Sulindac sulfoxide is an 
MsrA substrate that acts as a catalytic antioxidant: each cycle of sulindac reduction to 
sulindac sulfide, followed by oxidation of sulindac sulfide by ROS, is expected to neutralize 
one equivalent of ROS. Met oxidation results in the formation of equimolar quantities of two 
stereoisomerically unique Met sulfoxides: Met-S-sulfoxide and Met-R-sulfoxide, which are 
substrates of MsrA and the genetically unrelated MsrB repair enzyme, respectively 
(Moskovitz et al., 2000; Moskovitz et al., 2002). MsrA, which exhibits tumor suppressor 
activity for breast (De Luca et al., 2010) and liver (Lei et al., 2007) cancers, may function as 
a repair system for oxidized proteins and as a ROS scavenger in a cyclic reaction involving 
Met oxidation/reduction (Weissbach et al., 2005). Sulindac (sulfoxide or sulfide) is a 
specific substrate for MsrA but not MsrB (Weissbach et al., 2005). Since sulindac inhibited 
only half of RUNX2 activity and half of the activity was restored by sulindac after oxidation 
(Fig. 5C), the results are consistent with an MsrA-regulated RUNX2 activity where sulindac 
can neutralize H2O2 and restore RUNX2 activity. Noteworthy is that higher concentrations 
of sulindac or sulindac sulfide showed a distinct inhibition of RUNX2 DNA binding in 
H2O2 treated samples (Fig. 5C), consistent with inhibition of MsrA itself or other anti-
oxidants that regenerate MsrA. The catalytic antioxidant ability of sulindac is limited 
because it is not a substrate for MsrB. However, 100% of the RUNX2 activity was restored 
by DTT treatment at 37 °C after oxidation with H2O2 (Fig. 4). Therefore, nuclear extracts 
may contain both MsrA and MsrB activity. In future, it will be important to determine 
whether MsrB is also present in EC nuclear extracts and whether it regulates RUNX2 
activity.
The RUNX2 DNA-binding domain contains a critical Met residue, which is essential for 
binding of the RUNX2 cofactor Cbfβ and DNA-binding (Tahirov et al., 2001). The 
homologous Met in RUNX1 (Met106) is exposed on a planar, hydrophobic surface (Tahirov 
et al., 2001). Addition of oxygen may convert the normally flexible nonpolar side chain to a 
more rigid and polar species with a hydrophobicity index similar to that of lysine. Oxidized 
Met (MetO) has been detected in native proteins in vivo and is a modification that affects 
protein function (Oien and Moskovitz, 2008). Incubation of recombinant RUNX1 and MsrA 
in vitro resulted in reduction of MetO residues as detected with anti-MetO antibody (Fig. 6). 
Oxidative stress reduced the association of the RUNX2 binding partner, Cbfβ, with RUNX2. 
We showed that Cbfβ is present in the RUNX2:DNA binding complex (Underwood et al., 
2012). Therefore, MsrA most likely is associated with a complex containing DNA, RUNX2, 
and its cofactor Cbfβ, consistent with a redox-regulated DNA-binding complex. There are 
many examples of other transcription factors whose DNA interaction and transcriptional 
activities are redox regulated — such as p53 and Hif1-alpha (Hanson et al., 2005; Qutub and 
Popel, 2008). The need for regulation of redox status in the nucleus may arise from changes 
in oxidative conditions, maintenance of active transcriptional complexes, or may reflect 
rapid modulation of signaling events to control transcriptional activity (Hamanaka and 
Chandel, 2010). Therefore, RUNX2 may be a novel MsrA substrate with a redox-regulatable 
and functional Met residue. However, MsrA may regulate RUNX2 activity globally by 
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altering ROS balance to reverse Cys residue oxidation, which also regulates RUNX2 DNA 
binding.
Conclusions
Oxidative stress plays a role in age-associated pathologies and shortening of lifespan in 
rodents and other species (Lass et al., 1998; Stadtman et al., 2005). Compromised 
antioxidant defenses may account for reduced angiogenesis, vascular deficits, and neuronal 
dysfunction associated with aging (Moskovitz, 2005). The RUNX2 transcription factor 
regulates angiogenesis by activating specific target genes that control EC invasion, 
migration, and survival (Pierce et al., 2012; Qiao et al., 2006; Sun et al., 2001; Sun et al., 
2004). Our results show that (1) HG and oxidative stress inhibited RUNX2 DNA binding 
and EC differentiation, (2) the aldose reductase pathway mediated inhibition of RUNX2 and 
EC differentiation in HG, (3) substrates of Methionine sulfoxide reductase-A regulated 
RUNX2 DNA binding, and (4) Methionine sulfoxide reductase-A and RUNX proteins 
interacted to regulate oxidative damage. Further study of the novel redox pathways 
regulating this important transcription factor could lead to strategies to control EC redox 
balance, improve vessel normalization or inhibit angiogenesis (Cao and Langer, 2010).
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D-ELISA DNA-based enzyme-linked immunosorbent assay
DTT dithiothreitol
EMSA electrophoretic mobility shift assay
HAdEC human microvascular adipose-derived ECs (HAdEC)
HBME human bone marrow microvascular ECs
HG hyperglycemia
HMEC1 human microvascular dermal ECs (HMEC1)
HRVT Huvec retroviral telomerase
MetO methionine sulfoxide
MsrA Methionine sulfoxide reductase A
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PAO phenyl arsine oxide
RIN-r rat pancreatic β-cells
ROS reactive oxygen species
RUNX2 human Runt-related transcription factor
VAN vanadate
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Regulation of RUNX2 DNA binding by HG and oxidative stress. (A) Human bone marrow 
microvascular ECs (HBME), human adipose ECs (HAdEC), human microvascular dermal 
ECs (HMEC1), telomerized human umbilical vein ECs (HRVT), or rat pancreatic β-cells 
(RIN-r) were cultured in starvation media for 16 h and treated with 0, 5, 12.5, or 25 mM 
glucose for 4 h or with 10 mM of the anti-oxidant N-acetyl Cys (NAC). Nuclear extracts 
were prepared and RUNX2 DNA binding activity measured by EMSA with a RUNX2-
specific oligonucleotide. Assays were repeated three times. Relative band intensity is shown 
for a representative set of results, normalized to total protein in each lane. (B) Glucose and 
serum-starved ECs were treated with 5 mM or 25 mM glucose or with 5 mM glucose and 
the oxidants curcumin, H2O2 honokiol, HF-honokiol or the phosphatase inhibitors VAN or 
PAO before isolation of nuclear extracts. Relative band intensities are indicated. (C) 
Oxidants inhibit EC tube formation. ECs were treated with 5 mM glucose or glucose + 
oxidants (H2O2, diquat, honokiol, hexafluoro-honokiol, IBMX) or phosphatase inhibitors 
(PAO, orthovanadate), for 6 h on matrigel. Essentially similar results were obtained in three 
other experiments.
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RUNX2-mediated EC differentiation is regulated through aldose reductase in HG. (A) The 
aldose reductase inhibitor ranirestat (100 nM) was added to ECs cultured on matrigel and 
tube formation was measured in starved cells (0 mM glucose) or cells treated with 5 mM or 
25 mM glucose after 16 h. Bars represent mean area occupied by tubes; n = 4; *p < 0.01 
(ANOVA). (B) ECs were starved for 16 h and treated for 4 h with the indicated doses of 
glucose. Nuclear extracts were examined for RUNX2 DNA binding after treatment of cells 
with 25 mM glucose and the AR-selective inhibitor ranirestat (0–500 nM). Relative band 
intensity normalized to total protein is shown for a representative assay (repeated three 
times). Ranirestat (100 nM) prevented inhibition of DNA binding in HG (NS, not 
significant, p > 0.05; lane 2 vs lane 7).
Mochin et al. Page 19














HG regulates ROS production and redox status in ECs. (A) ECs were cultured in triplicate in 
the absence of glucose and serum for 16 h before treatment with 0, 5, or 25 mM glucose for 
4 h. Total ROS levels were measured after incubation with CDCF-DA. In some cases, cells 
treated with 5 mM glucose were also treated with H2O2, diquat, or mannitol or cells were 
treated with AR inhibitors (alrestatin, 10 μM; ranirestat, 1 μM) in the presence of 25 mM 
glucose. NS = not significant. (B) NADP:NADPH ratios (triplicate determination) were 
measured in response to glucose and AR inhibitors (alrestatin, 10 μM; ranirestat, 1 μM) (*p 
< 0.05, Student’s t-test; **p < 0.05, ANOVA). (C) GSH concentrations (μM) in response to 
glucose or glucose + AR inhibitors were measured after treatment as in panel B (*p < 0.05, 
ANOVA).
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Redox regulation of RUNX2 DNA binding. (A) EC nuclear extracts were treated with 
diamide (15 min) to specifically oxidize Cys residues followed by reduction with DTT (15 
min) at 24 °C. Diamide oxidation of Cys residues inhibited RUNX2 activity, which was 
reversible by DTT treatment at 24 °C (for untreated vs diamide, *p < 0.0015; for untreated 
vs diamide + DTT; NS, p < 0.06 m, not significant). H2O2 treatment (100 μM) inhibited 
DNA binding (p < 0.005), which was reversible only at 37 °C for 30 min (NS, p < 0.12; not 
significant relative to untreated). RUNX2-specific DNA binding was measured 
quantitatively by D-ELISA. (B) Comparison of RUNX2 DNA binding (triplicate 
determinations) in nuclear extracts incubated at 37 °C for 30 min. DTT (30 mM) prevented 
loss of RUNX2 activity. *p < 0.05 relative to no DTT. (C) Nuclear extracts treated with 100 
μM H2O2 showed low DNA binding. Addition of DTT (30 mM) after H2O2 treatment 
restored DNA-binding activity within 20 min at 37 °C. *p < 0.05 relative to H2O2 alone.
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Sulfoxide regulation of RUNX2 DNA binding activity. (A) MsrA is associated with 
RUNX2:DNA binding complexes. DNA binding (D-ELISA) was used to quantify RUNX2 
and MsrA binding to oligonucleotide containing RUNX2-binding sites. Secondary antibody-
HRP reaction monitored at A450 nm as described for D-ELISA. Absorbance from secondary 
antibody alone was subtracted from each value. All stock antibody concentrations were 1 
mg/ml. Mean ± SD calculated from triplicate samples. (B) Nuclear extracts from HBME 
cells were treated with H2O2 (100 μM), followed by DTT (30 mM) in the presence or 
absence of DMSO (0.1%). H2O2 treatment was for 30 min at RT. DMSO and DTT were 
added at 37 °C and incubated in a test tube for 20 min before adding to the assay plates. D-
ELISA was used to quantify DNA binding. DMSO inhibited restoration of RUNX2 activity 
by DTT after H2O2 treatment (*p < 0.05). (C) Nuclear extracts were treated with or without 
H2O2 (100 μM) in the presence or absence of the indicated concentrations of sulindac 
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(sulfoxide) or the reduced sulindac sulfide (1 nM to 500 μM). Sulindac sulfoxide inhibited 
RUNX2 DNA binding in the absence of DTT or H2O2 (top curves) (*p < 0.05 relative to 
sulindac sulfide). In the absence of DTT, sulindac sulfoxide or sulindac sulfide activated 
RUNX2 DNA binding after H2O2 treatment (lower curves) (p < 0.05 relative to untreated). 
All data points were in triplicate.
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MsrA-regulated oxidation of RUNX methionine residues. (A) EC nuclear extracts were 
treated with the indicated compounds or with recombinant MsrA. Each treatment was 
performed in triplicate and RUNX2 DNA binding was monitored kinetically after the 
addition of HRP substrate (absorbance 635 nm) in a 96-well plate. Shown are results after 
32 min (significant differences were noted between 10 and 32 min of reaction). p-Values 
relative to untreated (t-test): 1 μM H2O2 (p < 0.005); 1 μM H2O2 + 30 mM DTT (p > 0.05; 
NS); 30 mM DTT + MsrA or 1 μM H2O2 + 30 mM DTT + MsrA (p < 0.05). rMsrA 
increased RUNX2 DNA binding in the presence of H2O2 (*p < 0.05, ANOVA). (B) MsrA 
association with RUNX2 by co-immunoprecipitation (IP): representative gel from three 
determinations. ECs were treated in vivo with honokiol (10 μM) or H2O2 (100 μM). Nuclear 
extracts were isolated, immunoprecipitated with MsrA-specific antibody and immunoblotted 
with RUNX2 or MsrA-specific antibody. Recombinant MsrA control, lane 1; untreated 
Mochin et al. Page 24













cells, lane 2; cells + honokiol, lane 3; cells + H2O2, lane 4. Relative density of RUNX2 
(normalized to MsrA) in each lane is indicated as fold changes. (C) Live cells were starved 
for 16 h (0 mM glucose) and treated with glucose (5 mM) or glucose + H2O2 (100 μM). 
RUNX2 antibody was used for immuneprecipitation of RUNX2-associated Cbfβ cofactor. 
Relative density of Cbfβ (normalized to Runx2) in each lane is indicated as fold changes. 
(D) RUNX1 (a surrogate for RUNX2) is an MsrA substrate. Recombinant proteins rRUNX1 
or rMsrA were incubated individually or together at 24 °C or 37 °C for 30 min and resolved 
on SDS-PAGE. Western blot with specific antibody (Ab) detects Met-sulfoxide (MetO) or 
MsrA. Experiment was repeated with essentially similar results. Indicated are rRunx1 (49 
kDa), rRunx1 dimers (98 kDa), and rMsrA (26 kDa).
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